Improved tolerability and efficacy in epilepsy patients with extended-release carbamazepine.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 16116122.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The authors conducted a 3-month, prospective, open-label study assessing the effects of switching from immediate-release carbamazepine formulations to an equal total daily dose of carbamazepine extended-release capsules (CBZ-ERC) in adolescents and adults with epilepsy. Using validated, epilepsy-specific measures the authors found that switching to CBZ-ERC significantly improved patients' adverse events and quality-of-life measures. Switching to CBZ-ERC also improved seizure control.
Medical subject headings
- Anticonvulsants
- Carbamazepine
- Epilepsy